Minimal residual disease status is the prognostic determinant following high‐dose treatment for patients with multiple myeloma

Minimal residual disease status is the prognostic determinant following high‐dose treatment for patients with multiple myeloma

Abstract Background The presence of minimal residual disease (MRD+) following autologous stem cell transplantation (ASCT) in multiple myeloma represents a poor prognostic factor for progression‐free survival (PFS) and overall survival (OS). Methods At our department, we recommend lenalidomide mainte...

Full description

Bibliographic Details
Main Authors: Hareth Nahi, Gabriel Afram, Katarina Uttervall, Sandra Lockmer, Love Tätting, Gösta Gahrton, Muhammad Kashif, Evren Alici, Olga Stromberg, Monika Klimkowska, Johan Lund
Format: Article
Language:English
Published: Wiley 2023-11-01
Series:Cancer Medicine
Subjects:
minimum residual disease
multiple myeloma prognosis
Online Access:https://doi.org/10.1002/cam4.6640

Similar Items

Similar Items